Celldex shares crater after Pfizer dumps cancer vax pact; Abbott plan to sell vaccine unit put on hold

Vaccine Research

Shares of Celldex Therapeutics plunged late last week after Pfizer opted to pull out of their partnership to develop a new cancer vaccine. Story

Vical says it is planning to present final results from the company's Phase II trial for its TransVax therapeutic DNA vaccine to prevent cytomegalovirus reactivation and disease in immunosuppressed hematopoietic cell transplant patients. Vical release

The World Health Organization is pushing for new technology that allows for faster vaccine production. Story

The NIH's decision to take some 200 chimps out of retirement and relocate them to a lab in San Antonio for research purposes has triggered controversy and condemnations from animal rights groups. Story

A self-administered patch containing tiny microneedles may effectively deliver influenza virus-like particles through the skin and protect against potentially pandemic flu viruses such as H5N1. Release

Vaccine Market

Abbott Laboratories has called off the sale of its vaccines unit, which was acquired in the Solvay buyout. "We explored the option to potentially sell the business and determined it was in the best interest of Abbott and the vaccines business to retain it and integrate it into the company," said Abbott spokesman Scott Stoffell. Report

CVS says it will donate $5 million in flu vaccine shots to the uninsured. Report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.